Disease · MONDO_0044937

rectal carcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. rectal carcinoma. Diseases, record MONDO_0044937. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0044937

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: rectal carcinoma; Open Targets
Open Targets ID: MONDO_0044937; Open Targets
Other names: carcinoma of rectum, carcinoma of the rectum, rectum carcinoma; Open Targets
NCI Thesaurus: C9382; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 4 of its 12 drugs, from ClinicalTrials.gov; Open Targets

Drugs12

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
FLUOROURACIL	CHEMBL185	Small molecule	Phase 3	ClinicalTrials.gov	5	5	4	Drugs and targets
EDRECOLOMAB	CHEMBL2108955	Antibody	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
LANREOTIDE	CHEMBL1201185	Protein	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
LEUCOVORIN CALCIUM	CHEMBL1201138	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
OXALIPLATIN	CHEMBL414804	Small molecule	Phase 2/3	ClinicalTrials.gov	5	5	4	Drugs and targets
IRINOTECAN	CHEMBL481	Small molecule	Phase 2/3	ClinicalTrials.gov	3	3	2	Drugs and targets
LEUCOVORIN	CHEMBL1679	Small molecule	Phase 2/3	ClinicalTrials.gov	2	2	1	Drugs and targets
CAPECITABINE	CHEMBL1773	Small molecule	Phase 2	ClinicalTrials.gov	7	7	7	Drugs and targets
BEVACIZUMAB	CHEMBL1201583	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
DALOTUZUMAB	CHEMBL1743006	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 12

See all 12 drugs

Targets58

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
TYMS	Thymidylate synthase	2	Thymidylate synthase inhibitor	Phase 3	https://conductscience.org/library/genes/7298	Drugs and targets
COXFA4	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 2	https://conductscience.org/library/genes/4697	Drugs and targets
COXFA4L2	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 2	https://conductscience.org/library/genes/56901	Drugs and targets
EPCAM	Epithelial cell adhesion molecule	1	Epithelial cell adhesion molecule cross-linking agent	Phase 3	https://conductscience.org/library/genes/4072	Drugs and targets
GPD2	Glycerol-3-phosphate dehydrogenase, mitochondrial	1	Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor	Phase 2	https://conductscience.org/library/genes/2820	Drugs and targets
IGF1R	Insulin-like growth factor 1 receptor	1	Insulin-like growth factor I receptor antagonist	Phase 2	https://conductscience.org/library/genes/3480	Drugs and targets
MT-ND1	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 2	https://conductscience.org/library/genes/4535	Drugs and targets
MT-ND2	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 2	https://conductscience.org/library/genes/4536	Drugs and targets
MT-ND3	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 2	https://conductscience.org/library/genes/4537	Drugs and targets
MT-ND4	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 2	https://conductscience.org/library/genes/4538	Drugs and targets

1 to 10 of 58

See all 58 targets

Trials12

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00682786	Genotype-directed Neoadjuvant Chemoradiation for Rectal Carcinoma	Phase 2	135	2014-09-08	Rectal Carcinoma	FLUOROURACIL, IRINOTECAN	Its record names the disease	ClinicalTrials.gov
NCT02010567	Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer	Phase 1/2	32	2017-11-14	Rectal Cancer	CAPECITABINE, DAVAMOTECAN PEGADEXAMER	Its record names the disease	ClinicalTrials.gov
NCT01609231	A Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025)	Phase 2	11	2020-05-04	Rectal Neoplasms	DALOTUZUMAB, IRINOTECAN	Its record names the disease	ClinicalTrials.gov
NCT02017704	Chemoradiation or Brachytherapy for Rectal Cancer	Phase 2	9	2023-02-24	Rectal Cancer	CAPECITABINE, FLUOROURACIL, LEUCOVORIN, OXALIPLATIN	Its record names the disease	ClinicalTrials.gov
NCT00309517	Randomized Study on Neoadjuvant Radio-Chemotherapy in Rectal Carcinoma Dukes B and C	Phase 3	700		Rectal Cancer Dukes B, Dukes C	EDRECOLOMAB, FLUOROURACIL, LEUCOVORIN CALCIUM	Its record names the disease	ClinicalTrials.gov
NCT01333709	Multicenter Phase 2 Trial: a Tailored Strategy for Locally Advanced Rectal Carcinoma	Phase 2	150		Locally Advanced Malignant Neoplasm, Rectal Carcinoma	CAPECITABINE	Its record names the disease	ClinicalTrials.gov
NCT00297141	Preoperative Combined Radiochemotherapy for Patients With Rectal Carcinoma	Phase 2	60		Rectal Cancer	CAPECITABINE, OXALIPLATIN	Its record names the disease	ClinicalTrials.gov
NCT02000050	Phase II Study of Up-front Chemotherapy and Neo-adjuvant Short-course Radiotherapy for Resectable Rectal Carcinoma (COLORE)	Phase 2	52		Rectal Carcinoma	FLUOROURACIL, OXALIPLATIN	Its record names the disease	ClinicalTrials.gov
NCT01434147	Preoperative Combined Induction Chemotherapy With Capecitabine, Oxaliplatin, Bevacizumab and Radiotherapy	Phase 2	25		Rectal Cancer	BEVACIZUMAB, CAPECITABINE, OXALIPLATIN	Its record names the disease	ClinicalTrials.gov
NCT01372007	Influence of Somatuline Autogel 120mg on Post-operative Drainage After Total Mesorectum Excision for Rectumcarcinoma	Phase 3	24		Rectal Carcinoma	LANREOTIDE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 12

See all 12 trials

Comparisons in its trials6

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Good Risk (Thymidylate Synthase (TYMS)2/2, 2/3, 2/4) vs Poor Risk (Thymidylate Synthase (TYMS)3/3, 3/4): serious adverse events	16 of 96	12 of 35	131	NCT00682786	Trial comparisons
Dalotuzumab + Irinotecan vs Cetuximab + Irinotecan: deaths from any cause	1 of 6	2 of 5	11	NCT01609231	Trial comparisons
Dalotuzumab + Irinotecan vs Cetuximab + Irinotecan: serious adverse events	1 of 6	4 of 5	11	NCT01609231	Trial comparisons
IMRT and Capecitabine vs Endo-HDR: deaths from any cause	0 of 4	0 of 5	9	NCT02017704	Trial comparisons
IMRT and Capecitabine vs Endo-HDR: serious adverse events	1 of 4	2 of 5	9	NCT02017704	Trial comparisons
IMRT and Capecitabine vs Endo-HDR: Number of Patients With Pathologic Complete Response	0 of 2	2 of 5	7	NCT02017704	Trial comparisons

Papers from its trials7

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
33343722	RESULT	1	PubMed
15496622	RESULT	1	PubMed
34759247	DERIVED	1	PubMed
30858085	DERIVED	1	PubMed
28594714	DERIVED	1	PubMed
27784746	DERIVED	1	PubMed
21267531	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0044937

GET https://conductscience.org/api/diseases/v1/MONDO_0044937/targets?page=2

API reference For AI assistants